1-3 of 3
Barry Hancock, MD
Close
Sort by
Journal Articles

Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244

Peter W.M. Johnson, MD, FRCP, Alan Horwich, PhD, FRCR, MRCP, Andrew Jack, MD, FRCPath, Graham Mead, DM, FRCP, Barry Hancock, MD, FRCP, Paul Smith, Wendi Qian, Philippa Patrick, PhD, Andrew Pettitt, David Cunningham, Peter Hoskin, MD, FRCR
Journal: Blood
Blood (2008) 112 (11): 370.
https://doi.org/10.1182/blood.V112.11.370.370
Published: 2008
Journal Articles

Consolidation Radiotherapy Is Associated with Improved Outcomes after Chemotherapy for Advanced Hodgkin Lymphoma: Analysis of Results from the UKLG LY09 Trial (ISRCTN97144519)

Peter W.M. Johnson, MD, FRCP, Matthew R Sydes, John Radford, MD, FRCP, Michael Cullen, MD, FRCP, Sally Stenning, Barry Hancock, MD, FRCP
Journal: Blood
Blood (2008) 112 (11): 368.
https://doi.org/10.1182/blood.V112.11.368.368
Published: 2008
Journal Articles

Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.

Peter Johnson, MD, Peter Hoskin, MD, Alan Horwich, MD, Barry Hancock, MD, Paul Smith, Lindsey Stevens, Wendy Qian, John William Sweetenham, MD
Journal: Blood
Blood (2004) 104 (11): 311.
https://doi.org/10.1182/blood.V104.11.311.311
Published: 2004